JP2023551877A5 - - Google Patents
Info
- Publication number
- JP2023551877A5 JP2023551877A5 JP2023533310A JP2023533310A JP2023551877A5 JP 2023551877 A5 JP2023551877 A5 JP 2023551877A5 JP 2023533310 A JP2023533310 A JP 2023533310A JP 2023533310 A JP2023533310 A JP 2023533310A JP 2023551877 A5 JP2023551877 A5 JP 2023551877A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- cells
- composition according
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/133598 WO2022116086A1 (en) | 2020-12-03 | 2020-12-03 | Bcma-targeted car-t cell therapy for multiple myeloma |
| CNPCT/CN2020/133598 | 2020-12-03 | ||
| PCT/CN2021/135295 WO2022117068A1 (en) | 2020-12-03 | 2021-12-03 | Bcma-targeted car-t cell therapy for multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551877A JP2023551877A (ja) | 2023-12-13 |
| JP2023551877A5 true JP2023551877A5 (enExample) | 2024-12-12 |
Family
ID=79270135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533310A Pending JP2023551877A (ja) | 2020-12-03 | 2021-12-03 | Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20220265710A1 (enExample) |
| EP (1) | EP4255450A1 (enExample) |
| JP (1) | JP2023551877A (enExample) |
| KR (1) | KR20230118556A (enExample) |
| CN (1) | CN116888147A (enExample) |
| AR (1) | AR124248A1 (enExample) |
| AU (1) | AU2021392708A1 (enExample) |
| CA (1) | CA3203603A1 (enExample) |
| IL (1) | IL303312A (enExample) |
| JO (1) | JOP20230122A1 (enExample) |
| MA (1) | MA71426A (enExample) |
| MX (1) | MX2023006371A (enExample) |
| TW (1) | TW202237637A (enExample) |
| UY (1) | UY39555A (enExample) |
| WO (2) | WO2022116086A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021091945A1 (en) | 2019-11-05 | 2021-05-14 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy of multiple myeloma |
| CN116096498A (zh) * | 2020-05-04 | 2023-05-09 | 生物诊断有限公司 | 诊断设备 |
| WO2024146398A1 (zh) * | 2023-01-04 | 2024-07-11 | 北京艺妙神州医药科技有限公司 | 分离的抗体、包含该抗体的car及其用途 |
| WO2024206329A1 (en) | 2023-03-27 | 2024-10-03 | Modernatx, Inc. | Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof |
| CA3205511A1 (en) * | 2023-04-19 | 2025-03-17 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| WO2018028647A1 (en) * | 2016-08-10 | 2018-02-15 | Legend Biotech Usa Inc. | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| CN105777911B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
| SG10202012157QA (en) * | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN108395478A (zh) * | 2017-02-04 | 2018-08-14 | 上海恒润达生生物科技有限公司 | 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途 |
| SG11202008731XA (en) * | 2018-06-19 | 2020-10-29 | Nanjing Legend Biotech Co Ltd | Engineered cells and uses thereof |
| US20220177524A1 (en) * | 2018-07-26 | 2022-06-09 | Nanjing Legend Biotech Co., Ltd. | Nef-containing t cells and methods of producing thereof |
-
2020
- 2020-12-03 WO PCT/CN2020/133598 patent/WO2022116086A1/en not_active Ceased
-
2021
- 2021-12-02 US US17/540,736 patent/US20220265710A1/en active Pending
- 2021-12-02 TW TW110145018A patent/TW202237637A/zh unknown
- 2021-12-03 IL IL303312A patent/IL303312A/en unknown
- 2021-12-03 WO PCT/CN2021/135295 patent/WO2022117068A1/en not_active Ceased
- 2021-12-03 EP EP21838974.0A patent/EP4255450A1/en active Pending
- 2021-12-03 JP JP2023533310A patent/JP2023551877A/ja active Pending
- 2021-12-03 CN CN202180080095.0A patent/CN116888147A/zh active Pending
- 2021-12-03 CA CA3203603A patent/CA3203603A1/en active Pending
- 2021-12-03 UY UY0001039555A patent/UY39555A/es unknown
- 2021-12-03 US US18/039,420 patent/US20240000836A1/en active Pending
- 2021-12-03 MA MA71426A patent/MA71426A/fr unknown
- 2021-12-03 AU AU2021392708A patent/AU2021392708A1/en active Pending
- 2021-12-03 MX MX2023006371A patent/MX2023006371A/es unknown
- 2021-12-03 KR KR1020237018245A patent/KR20230118556A/ko active Pending
- 2021-12-03 AR ARP210103371A patent/AR124248A1/es unknown
-
2023
- 2023-05-30 JO JOJO/P/2023/0122A patent/JOP20230122A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023551877A5 (enExample) | ||
| JP7339733B2 (ja) | Ｃ３腎症を処置する方法 | |
| JP6918724B2 (ja) | 急性骨髄性白血病（ａｍｌ）のための新規併用治療 | |
| KR102276161B1 (ko) | 항체 제형 및 방법 | |
| DE60225914T2 (de) | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen | |
| EP2278960B1 (en) | Dosing regimen for a selective sip1 receptor agonist | |
| CN106102745B (zh) | 治疗和预防移植物抗宿主病的方法 | |
| JP2020203889A (ja) | 抗体製剤 | |
| US8591892B2 (en) | FTY720 increases CD74 expression and sensitizes cancer cells to anti-CD74 antibody-mediated cell death | |
| EA015560B1 (ru) | Способ лечения вирусного гепатита | |
| JP2009522371A5 (enExample) | ||
| JP2024540275A5 (enExample) | ||
| US20070274984A1 (en) | Methods for treating autoimmune diseases using a taci-ig fusion molecule | |
| US12324840B2 (en) | CD20-targeted antibody coupling pharmaceutical preparation | |
| JP2017524024A (ja) | 関節病態の治療 | |
| CN106794255A (zh) | 使用针对cd28的域抗体治疗系统性红斑狼疮的方法 | |
| JP2022508513A (ja) | がん治療のための併用療法 | |
| JP6494594B2 (ja) | 樹状細胞を含有する医薬およびその製造方法 | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| US20240415931A1 (en) | Methods of use and administration of encapsulated cells | |
| RU2322238C2 (ru) | Лечение ревматоидного артрита | |
| EP4648772A1 (en) | Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome | |
| CN119546336A (zh) | 用于治疗癌症的同种异体低免疫仿生纳米囊泡 | |
| Voltarelli et al. | Stem cell therapies for type 1 diabetes mellitus | |
| CA3279458C (en) | Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome |